Kornimate/medical-research-clean huggingface dataset:
faecal microbiota transplantation against chronic diarrhea in patients with systemic sclerosis

Conditions: Diarrhea; Systemic Sclerosis

Summary: this clinical trial aims to assess the safety and effectiveness of faecal microbiota transplantation (fmt) in improving chronic diarrhea symptoms among patients with systemic sclerosis.

the present study aims to assess the feasibility, pilot efficacy, and safety of fmt for patients with systemic sclerosis. participants will undergo two interventions in this present study. in the first intervention, participants are randomized 1:1 for either active fmt or placebo. this first intervention consists of two doses of fmt with a 3-7 day gap. in the second intervention, all participants receive 1 dose of active fmt treatment. this study design allows researchers to evaluate the safety of fmt in this patient group, and compare the effects of fmt in the fmt-treated group vs the placebo group, to see if fmt promotes remission of chronic diarrhea. furthermore, researchers will be able to gain insights into whether 2 initial doses are superior to one.

Eligibility criteria:
inclusion criteria: * participants \> 18 years * fulfilling and previously diagnosed with ssc according to the 2013 american college of rheumatology/european league against rheumatisms sss classification criteria\[23\] by rheumatologist or dermatologist. * chronic diarrea is defined as loose or watery stools, three or more times a day, a minimum of 50% of the days within the last four weeks. exclusion criteria: * inability to understand danish spoken or written and/or trial procedures. * known or anticipated pregnancy (excluded by male sex, postmenopausal women, or otherwise negative u-hcg) * previous treatment with fmt * treatment with antibiotics within the past 6 weeks * changes in morphine treatment within the past 4 weeks * ongoing infection with clostridioides difficile (negative pcr test) * known serious gastrointestinal disease or gi infection (diagnosed with e.g. inflammatory bowel disease and/or gastrointestinal cancer) * dysregulated thyroid disease (tsh) blood sample from previous consultations maximum 6 months old from * known intestinal stricture * planned mr scan within the study period * pacemaker/icd * previous abdominal surgery (minor surgical procedures ex. appendectomy is allowed) * changes in medicine that affect the gi tract within the past four weeks. * known severe end-organ disease * lung disease with forced vital capacity(fvc)\<50% and/or diffusing lung capacity for carbon monoxide (dlco) \<40% * severe heart failure with ejection fraction \<30% * end-stage kidney disease with glomeration rate\<30ml/min

Keywords: faecal microbiota transplantation (fmt) diarrhea systemic sclerosis chronic diarrhea
clinical trial of the s. flexneri-s. sonnei bivalent conjugate vaccine

Conditions: Dysentery; Dysentery, Shigella

Summary: the goal of this clinical trial is to evaluate the protective efficacy of s. flexneri-s. sonnei bivalent conjugate vaccine against diarrhea caused by shigella infection in infants and children aged 6 months to 5 years. researchers will observe the incidence of diarrhea of any severity due to shigella flexneri and shigella sonnei infection 30 days after full immunization. the subjects will receive 2 doses of vaccination.


Eligibility criteria:
inclusion criteria: * infants and children aged 6 months to 5 years. * legal guardians voluntarily agree to participate in the study and sign an informed consent form. * legal guardians agree to comply with the requirements of the clinical trial protocol and are willing and able to participate in all planned follow-ups. * the subject's guardian agrees that the subject should not abuse antibiotics. if needed，antibiotics should be used under the guidance of a doctor and avoid taking antibiotics on their own during the clinical trial. * based on medical history, physical examination, and the investigator's judgment, the subject is determined to be in good health. exclusion criteria: * history of confirmed bacterial dysentery in the past 6 months. * serious allergy to tetanus toxoid, history of severe allergies, fever above 39.5°c following previous vaccination with a prophylactic biological product. * currently suffering from serious intestinal diseases, symptoms of diarrhea, abdominal pain, or bloody purulent stools in the past 15 days. * diagnosed pathological jaundice currently. * confirmed diagnosis of thrombocytopenia or other coagulation disorders. * known or suspected immunological deficiencies (e.g., perianal abscesses indicating potential immune deficiency in infants and young children), long-term treatment (≥14 days) with immunosuppressants within half a year before vaccination (radiotherapy, chemotherapy, systemic corticosteroids ≥2 mg/kg/day, antimetabolites, cytotoxic drugs), or parents confirmed to have hiv infection. * receipt of immunoglobulins/blood products (except hepatitis b immunoglobulin) within 3 months before vaccination. * severe congenital anomalies (important organ function impairment), severe malnutrition, developmental disorders, severe hereditary diseases. * currently suffering from the following diseases: 1. severe liver or kidney diseases, cardiovascular diseases, malignant tumors, and other severe chronic diseases. 2. diagnosed serious infectious diseases, such as tuberculosis, viral hepatitis, etc. 3. severe asthma. 4. generalized rashes, dermatophytosis, skin suppuration, or blistering. 5. convulsions, epilepsy, encephalopathy, psychiatric disorders or family history of psychiatric disorders. * planning to participate or currently participating in other vaccine or drug clinical trials. * any condition that the investigators believe may affect the evaluation of the study.

Keywords: s. flexneri-s. sonnei bivalent conjugate vaccine
supine positioning for graft attachment after descemet membrane endothelial keratoplasty

Conditions: Fuchs' Endothelial Dystrophy

Summary: this randomized controlled trial evaluates the efficacy and safety of postoperative supine head positioning on graft attachment after descemet membrane endothelial keratoplasty in patients with fuchs' endothelial corneal dystrophy (fecd).

in descemet membrane endothelial keratoplasty (dmek), an air or gas bubble is inserted in the anterior chamber of the eye to keep the ultrathin endothelial corneal graft attached to the patients own cornea. supine positioning is thought to improve attachment by using the tamponade effect of the bubble. at present, it is unclear how long supine positioning is required. positioning regimens vary between one hour to over one week. in this trial, the investigators will assess if prolonged supine positioning for 5 days improves graft attachment and long-term outcomes compared to supine positioning for 1 day.

Eligibility criteria:
inclusion criteria: * diagnosis of advanced fuchs' endothelial corneal dystrophy (fecd) * indication for corneal endothelial transplantation (descemet membrane endothelial keratoplasty - dmek) exclusion criteria: * other corneal diseases (i.e. corneal scars, corneal dystrophies except fecd, corneal inflammation / infection) * regular use of drugs potentially affecting the cornea (i.e. amiodarone, chloroquine, triptan, isotretinoin, use of contact lenses in past four weeks, anesthetic eye drops) * diabetes mellitus with endorgan complications) * lack of fixation during corneal tomography * bedridden

Keywords: fuchs' endothelial corneal dystrophy descemet membrane endothelial keratoplasty incomplete graft attachment endothelial corneal graft detachment rebubbling (repeat injection of air or gas in the anterior chamber) supine positioning postoperative posture anterior segment optical coherence tomography neural network machine learning randomized controlled trial
study of time-restricted eating on weight loss.

Conditions: Obesity; Insulin Resistance

Summary: this is a randomized controlled trial studying the effects of time-restricted eating (tre) on weight loss in obese humans. obesity is the number one risk factor for type 2 diabetes mellitus (t2dm), and numerous studies demonstrate that weight loss is an effective strategy to prevent t2dm and improve the metabolic health of people diagnosed with t2dm. unfortunately, classical calorie restriction diets often fail to produce long-term weight loss due to low compliance, reduced resting metabolic rate (rmr), and other factors. therefore, novel dieting techniques must be explored in order to successfully treat obesity and prevent t2dm. studies in mice provide compelling evidence that feeding/fasting cycles can be altered to produce beneficial effects on weight loss and metabolic health markers in the absence of calorie restriction. limited research in human subjects suggests that this feeding paradigm may translate to human health as well, however, more research needs to be done in order to confirm this hypothesis. this study will determine if tre can lead to weight loss in obese human subjects. secondary outcomes include changes in body composition, homa-ir, hormonal and biochemical serum markers, rmr, and total energy expenditure (tee).


Eligibility criteria:
inclusion criteria: * bmi between 30-40 kg/m2 * participants must regularly consume breakfast (at least 5 days per week) * must speak, read, and comprehend english * access to reliable internet and/or wifi * must have a valid email address and phone number * must have a cellular phone with data plan exclusion criteria: * hiv or immunocompromised * current or past cancer diagnosis * pregnant, breastfeeding, or planned pregnancy in next 6 months * beginning or ending hormonal contraception in next 6 months * current diagnosis of type or type 2 diabetes * currently taking glucose-lowering drugs, statins, or oral steroids * history of gastric bypass surgery or any other weight-loss surgery * history of anorexia or bulimia * frequent travel across time zones or unusual work hours * unable to fast for prolonged periods due to medical condition * unable to stand for several minutes without aid * cannot lie down on cushioned table for 30 minutes * no internal metal artifacts that would alter body composition * unable to travel to ucsf for in-person testing * requires translator services

Keywords: weight loss diet time-restricted feeding
a study assessing esophageal function and remodeling with dupilumab compared with placebo for 24 weeks followed by 104 weeks open label in adult participants with eoe (remodeling with dupilumab in eosinophilic esophagitis long-term trial)

Conditions: Eosinophilic Oesophagitis

Summary: this is parallel, phase 4 study which consists of a 24 week (0.5 years) randomized, double blind, placebo controlled, 2-arm treatment period followed by an open label segment of 104 weeks (2 years) for a total of 128 weeks (2.5 years) to evaluate the effect of dupilumab treatment on esophageal function, and remodeling in adults with eosinophilic esophagitis. duration of study period (per participant) * screening period: up to 12 weeks before week 0 * randomized double-blind period: 24 weeks * open label period: 104 weeks * post investigational medicinal product (imp) intervention follow-up period: up to 12 weeks or until the participants switch to commercialized dupilumab, whatever comes first. there will be ten (10) site visits, and five (5) direct-to-participant imp delivery visits (except if prohibited by local regulatory authorities or if participant is not willing. in this case, imp will be dispensed at the study site).

the duration per participant will be up to 152 weeks.

Eligibility criteria:
inclusion criteria: * a documented diagnosis of eoe by endoscopic biopsy. * baseline endoscopic biopsies with a demonstration on central reading of intraepithelial eosinophilic infiltration. * history (by participant report) of an average of at least 2 episodes of dysphagia (with intake of solids) per week in the 4 weeks prior to screening. * body weight ≥40 kg. exclusion criteria: participants are excluded from the study if any of the following criteria apply: * other causes of esophageal eosinophilia or the following conditions: hypereosinophilic syndrome or eosinophilic granulomatosis with polyangiitis (churg strauss syndrome). * active helicobacter pylori infection. * history of achalasia, crohn's disease, ulcerative colitis, celiac disease, and prior esophageal surgery. * any esophageal stricture unable to be passed with a standard, diagnostic, 9 to10 mm upper endoscope or any critical esophageal stricture that requires dilation at screening. * history of bleeding disorders or esophageal varices. * treatment with swallowed topical corticosteroids within 8 weeks prior to baseline. * initiation or change of a food elimination diet regimen or reintroduction of a previously eliminated food group in the 6 weeks prior to screening. * participation in prior dupilumab clinical study or participants currently treated or have been treated with commercially available dupilumab or contraindicated to dupilumab per local labelling. the above information is not intended to contain all considerations relevant to a potential participation in a clinical trial
comparing the effect of tadalafil 5 mg/day to sildenafil 25 mg/day on neutrophil-lymphocyte and platelet-lymphocyte ratios in erectile dysfunction patients; and comparison of clinical response

Conditions: Erectile Dysfunction and Neutrophil Lymphocyte Ratio

Summary: 1- to evaluate the effect of using tadalafil 5mg/day or sildenafil 25mg/day in the treatment on these ratios and its clinical effect in erectile dysfunction patients.

erectile dysfunction (ed) is an inability to provide adequate erection to initiate or maintain any sexual activity. the ed prevalence in adult males is approximately 20%. cardiovascular diseases, diabetes mellitus(dm), chronic systemic diseases, smoking and obesity are among the aetiology of ed .in recent years, publications indicating that active inflammatory processes cause ed are increasing. in these studies where neutrophil- lymphocyte (nlr) and platelet-lymphocyte ratios (plr) were used as signs of inflammation, a significant relationship was found between diseases with these proportions .neutrophil-to-lymphocyte ratio (nlr) is a simple parameter to assess easily the inflammatory status of a subject. it has proven its usefulness in the stratification of mortality in major cardiac events , as a strong prognostic factor in several types of cancers , or as a predictor and a marker of inflammatory or infectious pathologies (such is pediatric appendicitis) and postoperative complications. through enhanced production of cytokines and expression of cellular adhesion molecules, the dysfunctional endothelium promotes inflammation within the vascular wall and sets the stage for initiation and progression of atherosclerotic lesions in both penile vasculature and in peripheral and coronary blood vessels. it has been shown that patients with vasculogenic ed have increased inflammatory activation compared to subjects without ed.there are numerous studies suggesting that phosphodiesterase-5(pde-5) inhibitors, which are the first-line therapy of ed, might be effective in reversing generalized endothelial dysfunction. chronic treatment restores endothelium-dependent relaxations at various sites of the vascular tree, even up to one week after cessation of the treatment . previous studies reported a chronic effect of sildenafil and tadalafil on endothelial function and pro-inflammatory markers/mediators including intercellular and vascular cell adhesion molecules-1 (icam-1 and vcam-1, respectively), high sensitivity c-reactive protein (hscrp), and interleukin-6

Eligibility criteria:
inclusion criteria: * male patients with mild,moderate and severe erectile dysfunction. * age from 25 to 60 years. exclusion criteria: * · severe uncontrolled medical condition(dm,htn). * patients under treatment with sublingual nitrate . * patients with blood diseases that affect sexual function (leukaemia). * patients using cytotoxic drugs or immunosuppressive drugs. * single patient.
rivaroxaban for valvular heart disease and atrial fibrillation trial -river trial

Conditions: Valvular Heart Disease

Summary: rivaroxaban for valvular heart disease and atrial fibrillation trial (river trial).

a phase 2, randomized, open label, non-inferiority clinical trial to explore the safety and efficacy of rivaroxaban compared with vitamin k antagonism in patients with atrial fibrillation with bioprosthetic mitral valves - river. main analysis for the primary endpoint are based on the restricted mean survival time (rmst) method.

Eligibility criteria:
inclusion criteria: 1. male and female patients aged \>18 years at time of inclusion 2. patients with persistent or paroxysmal atrial fibrillation or flutter with bioprosthetic mitral valves. * the patient must be able to give informed consent exclusion criteria: 1. cardiovascular-related conditions as known presence of cardiac thrombus or tumor * active endocarditis * uncontrolled hypertension 2. hemorrhage risk-related criteria * active internal bleeding * history of, or condition associated with, increased bleeding risk 3. concomitant conditions and therapies * history of previous thromboembolism with high risk of bleeding: * severe, disabling stroke (modified rankin score of 4-5, inclusive) within 3 months * acute thromboembolic events or thrombosis (venous/arterial) within the last 14 days prior to randomization * acute mi within the last 14 days prior to randomization * treatment with: chronic aspirin therapy \> 100 mg daily or dual antiplatelet therapy; intravenous antiplatelets; fibrinolytics; anticipated need for long-term treatment with a nonsteroidal antiinflammatory drug; systemic treatment with a strong inhibitor of cytochrome p450 3a4, such as ketoconazole or protease inhibitors; treatment with a strong inducer of cytochrome p450 3a4, such as rifampicin, phenytoin, phenobarbital, or carbamazepine. * anemia * pregnancy or breastfeeding or women of reproductive age not using effective contraceptive methods * calculated creatinine clearance bellow 30 ml/min * known significant liver disease or alanine aminotransferase n3× the upper limit of normal * previous participation in this study.

Keywords: bioprosthetic mitral valve valvular heart disease anticoagulant agents noacs rivaroxaban warfarin
efficacy of median nerve hydrodissection by hyalase versus midazolam in the treatment of carpal tunnel syndrome:

Conditions: Pain, Neuropathic

Summary: comparing efficacy of hyalase and midazolam in median nerve entrapement neuropathy


Eligibility criteria:
inclusion criteria: * adult patients (30 - 70 years old) complaining of carpal tunnel syndrome of 3 month duration or more , diagnosed axonal neuropathy using electrodiagnosis , nerve conduction study refractory to medical treatment for 2 months . exclusion criteria: * diabetic patients * pregnant population . * refusal to participate
tmtp1 targeting micro-metastasis ln in laparoscopic sln detection in cervical cancer

Conditions: Cervical Cancer; Sentinel Lymph Node

Summary: investigators aimed to determine the validity of the investigator's novel tumor targeted fluorescent peptide tmtp1-icg to increased accuracy of laparoscopic sln mapping


Eligibility criteria:
inclusion criteria: * without childbearing requirements at the time of consent. * figo stage ib1, iia1 cervical cancer and is a candidate for laparoscopy intervention, with lymph node dissection being a part of the surgical plan. * subject has provided written informed consent. exclusion criteria: * breast-feeding or pregnant. * ongoing participation in another clinical trial with an investigational drug with 3 months * own allergy towards icg and/or alcohol * diagnosis of bacterial vaginosis, fungal vaginitis, sexually transmitted diseases * patients with cardiac dysfunction or hepatic insufficiency or renal insufficiency
blood flow restriction training for age-related sarcopenia

Conditions: Sarcopenia in Elderly

Summary: brief title: safe exercise for age-related muscle loss in hospitalized seniors summary: this study compares two exercise methods to help older hospital patients (age 65+) rebuild muscle strength after being diagnosed with sarcopenia (age-related muscle loss). we want to know if using special pressure cuffs during light exercise works better than traditional strength training alone. who can join: hospitalized seniors with stable health conditions excludes those with severe disabilities, dementia, or certain blood circulation problems what we'll do: 40 participants will be randomly assigned to either: traditional training group: uses weights/bands at 65-75% max capacity arm/leg exercises 3x/week for 4 weeks pressure cuff training group: uses special cuffs on arms/thighs during lighter exercises (20% max capacity) same exercise frequency with controlled pressure for safety what we'll measure: handgrip strength (main test at 0/4/12 weeks) walking speed, balance tests, quality of life surveys any side effects like dizziness/nausea safety first: doctors will check your health before starting. nurses will monitor every session. we use medical-grade cuffs with safe pressure limits (arm: 80-100mmhg, thigh: 150-200mmhg). you can stop anytime if uncomfortable. why this matters: this could help hospitalized seniors regain strength faster using gentler exercises. all activities are supervised by rehabilitation specialists at west china hospital, with ethics committee approval (irb number required).


Eligibility criteria:
inclusion criteria: * hospitalized patients aged ≥65 years * diagnosed with sarcopenia per ewgsop2019 criteria * acute medical conditions stabilized for ≥4 weeks (e.g., resolved infections, controlled heart failure) exclusion criteria: * severe disability (barthel index ≤40) * significant cognitive impairment (mmse ≤18) or major psychiatric disorders (dsm-5 criteria) * contraindications to blood flow restriction training: * history/predisposition to deep vein thrombosis * coagulopathy (inr \>1.5, platelets \<100×10⁹/l) * symptomatic varicose veins (ceap class c4-c6) * uncontrolled hypertension (bp \>160/100 mmhg) * chronic lymphedema (isl stage ii-iii) * peripheral artery disease (abi ≤0.7) * active systemic infection (crp \>10 mg/l) * malignancy (except non-melanoma skin cancer) * severe renal impairment (egfr \<30 ml/min/1.73m²) * acute coronary syndrome within 3 months